Emergent BioSolutions Inc. (NYSE:EBS) stock rose Friday following the FDA approval of new multipack configurations of over-the-counter NARCAN Nasal Spray.
Emergent BioSolutions announced that the U.S. Food and Drug Administration (FDA) has approved its supplemental New Drug Application (sNDA) for new 6-count and 24-count multipack configurations of NARCAN Nasal Spray.
NARCAN Naloxone HCl Nasal Spray 4 mg is the first FDA-approved, over-the-counter 4 mg naloxone product for the emergency treatment of opioid overdose.
The approval aims to enhance distribution flexibility for partners involved in high-volume naloxone distribution.
The new multipack options will be available soon through NARCANDirect, Emergent’s proprietary ordering platform, complementing the recent FDA approval of the NARCAN Nasal Spray Carrying Case.
Since its launch in 2016, over 85 million doses of NARCAN have been distributed across the U.S. and Canada, underscoring the product’s critical role in addressing opioid overdose emergencies.
Technical Analysis
Emergent BioSolutions is currently trading 2.9% below its 20-day simple moving average (SMA) and 7.1% below its 50-day SMA, indicating some short-term weakness. However, the stock has performed well over the past 12 months, gaining approximately 14.21%, and is positioned closer to its 52-week high than its low, reflecting a generally positive long-term trend.
The RSI is at 41.16, which is considered neutral territory, suggesting that the stock is neither overbought nor oversold. Meanwhile, MACD is below its signal line, indicating bearish pressure on the stock.
The combination of neutral RSI and bearish MACD suggests mixed momentum for Emergent BioSolutions.
- Key Resistance: $11.50
- Key Support: $10.50
Sector Performance
Emergent BioSolutions is outperforming the Healthcare sector, which is currently ranked 2 out of 11 sectors, showing no change from the previous trading day. Despite a 1.18% decline in the sector over the past 30 days, Emergent’s recent news has positioned it favorably against its peers.
The Healthcare sector’s performance has been mixed, with a 2.83% gain over the last 90 days, indicating some recovery potential. Emergent’s stock is benefiting from positive sentiment surrounding its product offerings, which may help it maintain its upward trajectory in a challenging market environment.
The countdown is on: Emergent BioSolutions, Inc. is set to report earnings on February 26, 2026.
- EPS Estimate: 32 cents (Up from 5 cents YoY)
- Revenue Estimate: $216.50 million (Up from $194.70 million YoY)
- Valuation: P/E of 8.2x (Indicates value opportunity)
Analyst Consensus & Recent Actions: The stock carries a Buy Rating with an average price target of $45
Benzinga Edge scorecard for Emergent BioSolutions:
- Value: Strong (Score: 84.14) — The stock is considered undervalued relative to its peers.
- Quality: Strong (Score: 91.62) — The company maintains a healthy balance sheet.
- Momentum: Bullish (Score: 72.97) — The stock is outperforming the broader market.
The Verdict: Emergent BioSolutions’ Benzinga Edge signal reveals a strong position in terms of value and quality, indicating that the stock may offer a compelling investment opportunity. The positive momentum score further suggests that the stock is likely to continue its upward trend, especially with the recent FDA approval driving interest.
Top ETF Exposure
- Schwab Fundamental US Small Company Index ETF (NYSE:FNDA): 0.33% Weight
- Invesco FTSE RAFI US 1500 Small-Mid ETF (NASDAQ:PRFZ): 0.42% Weight
EBS Price Action: Emergent BioSolutions shares were up 1.94% at $11.06 during premarket trading on Friday, according to Benzinga Pro data.
Photo by Tada Images via Shutterstock
